Prostate cancer combo trial pulled before it began
NCT ID NCT06528210
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study was designed to test whether adding the immunotherapy drug pembrolizumab (Keytruda) to standard hormone therapy and radiation could improve outcomes for men with high-risk localized prostate cancer. The trial was withdrawn before enrolling any participants, so no results are available. The goal was to see if the combination could eliminate cancer cells in the prostate and control the disease long-term.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
pembrolizumab (Keytruda) plus hormone therapy (bicalutamide and GnRH agonists) and radiation therapy
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STAGE I PROSTATE CANCER AJCC V8 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.